PHAR - What's Going On With Netherlands-Based Biopharma Company Pharming Shares Today? | Benzinga
Pharming Group (NASDAQ: PHAR) updated its full-year 2023 guidance, including RUCONEST and Joenja revenues, and a progress update on the U.S. launch of Joenja (leniolisib) for APDS.
The company expects revenue to increase by 19% to about $245 million, with RUCONEST revenues projected to be higher by 10% to around $227 million, significantly exceeding their previous guidance of low single-digit growth guidance.
Also, PHAR sees Joenja revenues of about $18 million, led by an increase in patients ...